This application is for the renewal of the NIDA P30 Center on Intersystem Regulation by Drugs of Abuse at Temple University. The Center has been successful in catalyzing interdisciplinary research, enhancing productivity, and creating synergy. The Core facilities have enabled individual researchers to extend their funded projects, brought new researchers into the field of substance abuse, and created a scientifically exciting atmosphere that resulted in successful recruitment of new faculty. This renewal application requests support for five Research Support Cores: Animal Models and Behavioral Testing, Biochemical Pharmacology, Cell and Immunology, Integrative Pharmacology, and Molecular Biology Cores, as well as Pilot Project Core and the Administrative Core. Changes in this renewal application include restructuring the Cores, addition of new key investigators who bring added expertise, and additional state-of-the-art innovative technologies, all of which will add major strengths to the Center. The NIDA P30 Core Center will support primarily preclinical research on drugs of abuse and addiction, with translational applications. Major integrative themes of the Center are 1) mechanisms of addiction and identification of novel therapeutic targets; 2) effects of drugs of abuse on HIV infection and other endpoints such as pain and behavior; 3) neuroimmune interactions, including cross-talk between opioids, cannabinoids and chemokines as related to pain, inflammation, and HIV; and 4) analysis of drug combinations. The Cores and their investigators have the ability to attack research problems from multiple levels, with expertise in molecular, cellular, immunological, pharmacological and behavioral approaches. This unique aspect of the Center encourages multi-disciplinary collaborations to best address novel hypotheses and significantly advance individual research programs. The NIDA P30 Core Center will provide cutting-edge technologies to the 25 NIH-funded research projects identified in the proposal as related to NIDA's mission, as well as our NIDA-supported trainees. The Center has, and will continue to, enhance synergy and productivity, and to stimulate innovative scientific discoveries that will result in new knowledge to bear on substance abuse.

Public Health Relevance

Drug abuse and addiction continue to be major public health problems with enormous personal, societal, and public health costs. The goal of Temple's NIDA P30 Center is to provide state-of-the-art resources for investigators to study the impact of drugs of abuse on physiological and pathological processes. The Core facilities with enhance and expand the scope of research on drugs of abuse, thus facilitating important scientific discoveries with the overall aim of substance abuse and its associated harm.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Tsai, Shang-Yi Anne
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Temple University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Ramirez, Servio H; Andrews, Allison M; Paul, Debayon et al. (2018) Extracellular vesicles: mediators and biomarkers of pathology along CNS barriers. Fluids Barriers CNS 15:19
Brailoiu, Eugen; Barlow, Christine L; Ramirez, Servio H et al. (2018) Effects of Platelet-Activating Factor on Brain Microvascular Endothelial Cells. Neuroscience 377:105-113
Barbe, Mary F; Massicotte, Vicky S; Assari, Soroush et al. (2018) Prolonged high force high repetition pulling induces osteocyte apoptosis and trabecular bone loss in distal radius, while low force high repetition pulling induces bone anabolism. Bone 110:267-283
Gentile, Taylor A; Simmons, Steven J; Barker, David J et al. (2018) Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. Addict Biol 23:247-255
Hicks, Callum; Huang, Peng; Ramos, Linnet et al. (2018) Dopamine D1-Like Receptor Agonist and D2-Like Receptor Antagonist (-)-Stepholidine Reduces Reinstatement of Drug-Seeking Behavior for 3,4-Methylenedioxypyrovalerone (MDPV) in Rats. ACS Chem Neurosci 9:1327-1337
Dziedowiec, Emily; Nayak, Sunil U; Gruver, Keenan S et al. (2018) Mu Opioid Receptor Agonist DAMGO Produces Place Conditioning, Abstinence-induced Withdrawal, and Naltrexone-Dependent Locomotor Activation in Planarians. Neuroscience 386:214-222
Simmons, Steven J; Gregg, Ryan A; Tran, Fionya H et al. (2018) Comparing rewarding and reinforcing properties between 'bath salt' 3,4-methylenedioxypyrovalerone (MDPV) and cocaine using ultrasonic vocalizations in rats. Addict Biol 23:102-110
Hill, Jeremy D; Zuluaga-Ramirez, Viviana; Gajghate, Sachin et al. (2018) Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis. Br J Pharmacol :
Cotto, Bianca; Li, Hongbo; Tuma, Ronald F et al. (2018) Cocaine-mediated activation of microglia and microglial MeCP2 and BDNF production. Neurobiol Dis 117:28-41
Ward, Sara Jane; Castelli, Francesca; Reichenbach, Zachary W et al. (2018) Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia. Life Sci 195:1-5

Showing the most recent 10 out of 343 publications